EnzymeImmunoassayforthequantitativeDeterminationofhumanInsulin-likeGrowthFactorBindingProtein-2(IGFBP-2)inhumanserum,EDTA-plasmacerebrospinalfluid,breastmilk,amnionticfluid,salivaandcellculturemedium.

TheadvantagesofourIGFBP-2ELISAare:
-measurementoftotalIGFBP-2concentrationinserum,plasmaandinotherhumanbodyfluids
-singlestandardswith2,10,20,40and80ng/mL
-totalIncubationtimeofonly1.75hours
-2ControlsareprovidedforqualitycontrolpurposesaccordingGLP
-ready-to-useAntibodyConjugate
-nosampleextractionneeded
-Microtiterplateseperatelybreakapart

CLINICALIMPLICATIONS

TheIGFBP-2concentrationisage-dependentinblood.Normalvaluesforhealthyindividuals(1.5to>70years)wereevaluatedforthisassay.SupplementaryparametertoIGFBP-3inthediagnosisofgrowthdisorders(IGFBP-2/IGFBP-3ratio),IGFBP-2isaninhibitorofgrowthhormoneaction.
Progression-dependenttumorMarkerinleukaemia,astrocysticCNStumors,prostate-,suprarenalcortex-,hepatocellularandothercarcinomas.

IGFBP-2isalsoananti-agingparameter,asamarkerofphysiologicalfunctionality.

Insulin-likegrowthfactors(IGFs)regulatetheproliferation,differentation,apoptose,celladhesionandmetabolisminvarioustissuesandcelltypes.TheIGF-I,whichisproducedmainlyinliverundertheinfluenceofgrowthhormone(GH),regulatesashormonethelineargrowthofthebonesandtheprocessofsexualmaturity,whileIGF-IIismainlyagrowthfactoroffetaltissue.TheBIOLOGicalactionsofIGFovertheIGF-Type-IreceptoraremodulatedvariablythroughtheIGFbindingproteins(IGFBP-1to-6).IGFBP-2is,afterIGFBP-3,thesecondmostfrequentIGFBPinthehumanblood.IGFs,especiallytumortypicalpro-IGF-formsandhormonesregulatetheexpressionofIGFBP-2,GHeffectistherebyinhibiting.AtcellularlevelIGFBP-2seemstostimulatetheproliferationanddisseminationofsolidtumorsviaanIGFindependentmechanism.

PHYSIOLOGICALMEANING
IGFBP-2isaunglycosylatedpolypetideof31.3kDa,whichformsbinaryIGF-complexesandshowsnocircADIanrhythminthecirculation.TheserumconcentrationofIGFBP-2increasesinfasting,aftermajorsurgeryandaftertrauma,buttheincreasingoftheconcentrationismostintensiveinmalignantdiseases.ThecorrelationoftheIGFBP-2leveltothedegreeofprogressionisastrikingfeatureinvarioustumortypesasisthenormalizationoftheIGFBPserumlevelsafterremission.DuringtheGH-therapy,e.g.inshortstatureandinGHabuse(doping)theIGFBP-2leveldecreases.
InTrisomy18IGFBP-2inmaternalserumisdecreasedandIGFBP-1isincreased;thereforetheratioIGFBP-2/IGFBP-1isamarkerforthischromosomeabnormality.